Vaccination Strategies Against Zika Virus

Overview

Journal Curr Opin Virol

Publisher Elsevier

Specialty Microbiology

Date 2017 Apr 23

PMID 28432975

Citations 29

Authors

Estefania Fernandez

Michael S Diamond

Affiliations

Soon will be listed here.

Abstract

The epidemic emergence of Zika virus (ZIKV) in 2015-2016 has been associated with congenital malformations and neurological sequela. Current efforts to develop a ZIKV vaccine build on technologies that successfully reduced infection or disease burden against closely related flaviviruses or other RNA viruses. Subunit-based (DNA plasmid and modified mRNA), viral vectored (adeno- and measles viruses) and inactivated viral vaccines are already advancing to clinical trials in humans after successful mouse and non-human primate studies. Among the greatest challenges for the rapid implementation of immunogenic and protective ZIKV vaccines will be addressing the potential for exacerbating Dengue virus infection or causing Guillain-Barré syndrome through production of cross-reactive immunity targeting related viral or host proteins. Here, we review vaccine strategies under development for ZIKV and the issues surrounding their usage.

Citing Articles

The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections.

You H, Jones M, Gordon C, Arganda A, Cai P, Al-Wassiti H Clin Microbiol Rev. 2023; 36(1):e0024121.

PMID: 36625671 PMC: 10035331. DOI: 10.1128/cmr.00241-21.

Host immune response against DENV and ZIKV infections.

Sekaran S, Ismail A, Thergarajan G, Chandramathi S, Rahman S, Ram Mani R Front Cell Infect Microbiol. 2022; 12:975222.

PMID: 36159640 PMC: 9492869. DOI: 10.3389/fcimb.2022.975222.

Emerging trends of research on mRNA vaccines: A co-citation analysis.

Chen J, Zhang T, Lu Y, Yang X, Ouyang Z Hum Vaccin Immunother. 2022; 18(6):2110409.

PMID: 36018287 PMC: 9746488. DOI: 10.1080/21645515.2022.2110409.

Zika M-A Potential Viroporin: Mutational Study and Drug Repurposing.

Tomar P, Krugliak M, Singh A, Arkin I Biomedicines. 2022; 10(3).

PMID: 35327443 PMC: 8944957. DOI: 10.3390/biomedicines10030641.

A modified age-structured SIR model for COVID-19 type viruses.

Ram V, Schaposnik L Sci Rep. 2021; 11(1):15194.

PMID: 34312473 PMC: 8313685. DOI: 10.1038/s41598-021-94609-3.

References

Durbin A, Kirkpatrick B, Pierce K, Carmolli M, Tibery C, Grier P . A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis. 2016; 214(6):832-5. PMC: 4996143. DOI: 10.1093/infdis/jiw067. View

Honein M, Dawson A, Petersen E, Jones A, Lee E, Yazdy M . Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy. JAMA. 2016; 317(1):59-68. DOI: 10.1001/jama.2016.19006. View

Charles A, Christofferson R . Utility of a Dengue-Derived Monoclonal Antibody to Enhance Zika Infection In Vitro. PLoS Curr. 2016; 8. PMC: 5026288. DOI: 10.1371/currents.outbreaks.4ab8bc87c945eb41cd8a49e127082620. View

Russell K, Hills S, Oster A, Porse C, Danyluk G, Cone M . Male-to-Female Sexual Transmission of Zika Virus-United States, January-April 2016. Clin Infect Dis. 2016; 64(2):211-213. DOI: 10.1093/cid/ciw692. View

Shen S, Shi J, Wang J, Tang S, Wang H, Hu Z . Phylogenetic analysis revealed the central roles of two African countries in the evolution and worldwide spread of Zika virus. Virol Sin. 2016; 31(2):118-30. PMC: 8193378. DOI: 10.1007/s12250-016-3774-9. View

Heinz F, Stiasny K . Flaviviruses and flavivirus vaccines. Vaccine. 2012; 30(29):4301-6. DOI: 10.1016/j.vaccine.2011.09.114. View

Capeding M, Tran N, Hadinegoro S, Ismail H, Chotpitayasunondh T, Chua M . Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014; 384(9951):1358-65. DOI: 10.1016/S0140-6736(14)61060-6. View

Frieden T, Schuchat A, Petersen L . Zika Virus 6 Months Later. JAMA. 2016; 316(14):1443-1444. DOI: 10.1001/jama.2016.11941. View

Mandl C, Allison S, Holzmann H, Meixner T, Heinz F . Attenuation of tick-borne encephalitis virus by structure-based site-specific mutagenesis of a putative flavivirus receptor binding site. J Virol. 2000; 74(20):9601-9. PMC: 112392. DOI: 10.1128/jvi.74.20.9601-9609.2000. View

10.

Bonaparte M, Dweik B, Feroldi E, Meric C, Bouckenooghe A, Hildreth S . Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from south-east Asia and India. BMC Infect Dis. 2014; 14:156. PMC: 3994458. DOI: 10.1186/1471-2334-14-156. View

11.

DICK G, KITCHEN S, HADDOW A . Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952; 46(5):509-20. DOI: 10.1016/0035-9203(52)90042-4. View

12.

Musso D, Nilles E, Cao-Lormeau V . Rapid spread of emerging Zika virus in the Pacific area. Clin Microbiol Infect. 2014; 20(10):O595-6. DOI: 10.1111/1469-0691.12707. View

13.

Halstead S, Mahalingam S, Marovich M, Ubol S, Mosser D . Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10(10):712-22. PMC: 3057165. DOI: 10.1016/S1473-3099(10)70166-3. View

14.

Nelson S, Jost C, Xu Q, Ess J, Martin J, Oliphant T . Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 2008; 4(5):e1000060. PMC: 2330159. DOI: 10.1371/journal.ppat.1000060. View

15.

Barba-Spaeth G, Dejnirattisai W, Rouvinski A, Vaney M, Medits I, Sharma A . Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016; 536(7614):48-53. DOI: 10.1038/nature18938. View

16.

Gotuzzo E, Yactayo S, Cordova E . Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years. Am J Trop Med Hyg. 2013; 89(3):434-44. PMC: 3771278. DOI: 10.4269/ajtmh.13-0264. View

17.

Ferraro B, Morrow M, Hutnick N, Shin T, Lucke C, Weiner D . Clinical applications of DNA vaccines: current progress. Clin Infect Dis. 2011; 53(3):296-302. PMC: 3202319. DOI: 10.1093/cid/cir334. View

18.

P Monath T, McCarthy K, Bedford P, Johnson C, Nichols R, Yoksan S . Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine. 2002; 20(7-8):1004-18. DOI: 10.1016/s0264-410x(01)00457-1. View

19.

Yasui K . Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J Immunol. 1988; 141(10):3606-10. View

20.

Barrett A, Teuwen D . Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place?. Curr Opin Immunol. 2009; 21(3):308-13. DOI: 10.1016/j.coi.2009.05.018. View